1. Amankwah, E.K., Conley, A.P., and Reed, D.R., Epidemiology and therapies for metastatic sarcoma, Clin. Epidemiol., 2013, vol. 5, pp. 147–162.
2. Ritter, J. and Bielack, S.S., Osteosarcoma, Ann. Oncol., 2010, vol. 21, suppl. 7, pp. 320–325.
3. Hattinger, C.M. and Serra, M., Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma, Expert Opin. Drug Metab. Toxicol., 2015, vol. 11, no. 9, pp. 1449–1463.
4. Byrgazov, K., Anderson, C., Salzer, B., Bozsaky, E., Larsson, R., Gullbo, J., Lehner, M., Lehmann, F., Slipicevic, A., Kager, L., Fryknäs, M., and Taschner-Mandl, S., Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide, Ther. Adv. Med. Oncol., 2020, vol. 12, e1758835920937891.
5. Vorontsova, J.E., Cherezov, R.O., Kuzin, B.A., and Simonova, O.B., Aryl-hydrocarbon receptor as a potential target for anticancer therapy, Biochem. (Moscow), Suppl., Ser. B Biomed.
Chem., 2019, vol. 13, no. 1, pp. 36–54.